UBC's worldwide experience and flexible resource capacity management approach recently helped us complete enrollment for one manufacturer’s study nearly four months ahead of schedule. Our recent blog post delves into the details.
The development of innovative therapies calls for innovative teams with clinical expertise, a passion for patient care and the vision to create medicine that has the potential to positively affect patient populations of one to one million. For these reasons, UBC welcomes Don Gabriel , MD, PhD, to our Global Clinical Development & Operations team.
You’ve heard it a thousand times in our business: You’re not buying the service, you’re buying the people. I was fortunate enough to build our clinical team in Europe from the ground up, so I know better than anyone how true that statement is.
When I joined the organisation in 2008, I was the first European-based employee for UBC. I rented offices in a three-story, converted Victorian house in central London, which we still fondly refer to as the “old house,” and started seeking talented professionals to join me.
As technology takes an even greater hold of healthcare, big data and its uses within all facets of improving patient care is instigating an evolution. Manufacturers are feeling more pressure to realize continued success, while streamlining processes and cutting costs. As these pressures build, traditional methods in clinical development are no longer providing desired results. To achieve more impact, the industry is being asked to take a fresh look at standard processes and the available data.
When working to operationalize clinical trial studies, the slower to launch, the more potential profit your company is losing. And although site identification is a key hurdle in getting studies off the ground, preparing a study is not a one-pronged approach. Take a minute to think about this analogy: Most people would be ecstatic to own a new luxury car, but what good is it without fuel to get it started?
The increased use and importance of observational studies necessitates sponsor evaluation of standard operating procedures for clinical trials. Often the focus of that evaluation is on methodology, structure, and resulting evidence, but it is just as critical that the technology details be evaluated as well. In the second part of our series, we examine additional facets that should be considered during development of platforms for registries and observational programs.
In-depth study and understanding of the disease or condition for which a drug or biologic is being developed is essential to the scientific foundation of any clinical development program. That’s why incorporating a natural history of disease study to evaluate patients who have been diagnosed with a specific condition or disease is well worth manufacturers’ time and effort.
A natural history study is a way to:
Today kicks off the 23rd annual Partnerships in Clinical Trials (PCT) conference where we’re looking forward to connecting with many of our industry colleagues, having a little fun, and taking time to give back.
For 23 years, the Partnerships in Clinical Trials conference has provided an event for key stakeholders in the clinical trials arena. From March 30 to April 2, more than 1,300 clinical executives will gather in Las Vegas to discuss this dynamic industry.